Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radium-223 chloride · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Radium-223 dichloride (Xofigo, BAY 88-8223) | EXPERIMENTAL | Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy. |
| Radium-223 chloride (Xofigo, BAY88-8223) | EXPERIMENTAL | The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg). |
| Name | Type | Description |
|---|---|---|
| Radium-223 chloride (BAY88-8223) | DRUG | The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.). |
Inclusion Criteria: * Patient is female, and either post-menopausal (cessation of menses for more than 1 year) or surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of childbearing potentia...
Top 20 of 92 competitors
Radium-223 chloride is an investigational oncology drug being studied for use in breast cancer and prostate cancer. It is being developed by Bayer AG. Clinical trials have focused on patients with bone metastases from these cancers, including a Phase 2 study in breast cancer patients with bone dominant disease.
Radium-223 chloride is a small molecule that acts as a radiopharmaceutical, targeting bone metastases. It delivers alpha radiation to areas of increased bone turnover, which are common sites of metastasis in prostate and breast cancer. This mechanism is designed to damage tumor cells in the bone while limiting exposure to surrounding healthy tissue.
Radium-223 chloride is being developed by Bayer AG, a German pharmaceutical company traded on the OTC market under the ticker BAYRY. Bayer has conducted clinical trials of this compound in both prostate cancer and breast cancer patients with bone metastases.
Radium-223 chloride is in Phase 2 clinical development for breast cancer. It has completed a Phase 1 trial in prostate cancer and a Phase 2 trial in breast cancer. The drug is investigational and has not been approved by regulatory authorities for any indication.
Radium-223 chloride has been studied in two completed clinical trials. NCT00748046 was a Phase 1 study in prostate cancer patients with skeletal metastases, enrolling 10 participants in the United States. NCT01070485 was a Phase 2 study in breast cancer patients with bone dominant disease, enrolling 23 participants in Belgium, Norway, and the United Kingdom.
Yes, Radium-223 chloride is also known as Alpharadin. Clinical trial records refer to the compound as both Radium-223 chloride and Alpharadin, with one trial titled "Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton."